Molecular Profiling of 888 Pediatric Tumors Informs Future Precision Trials and Data-sharing Initiatives in Pediatric Cancer

To inform clinical trial design and real-world precision pediatric oncology practice, we classified diagnoses, assessed the landscape of mutations, and identified genomic variants matching trials in a large unselected institutional cohort of solid tumors patients sequenced at Dana-Farber / Boston Children's Cancer and Blood Disorders Center. Tumors were sequenced with OncoPanel, a targeted next-generation DNA sequencing panel. Diagnoses were classified according to the International Classification of Diseases for Oncology (ICD-O-3.2). Over 6.5 years, 888 pediatric cancer patients with 95 distinct diagnoses had successful tumor sequencing. Overall, 33% (n = 289/888) of patients had at least 1 variant matching a precision oncology trial protocol, and 14% (41/289) were treated with molecularly targeted therapy. This study highlights opportunities to use genomic data from hospital-based sequencing performed either for research or clinical care to inform ongoing and future precision oncology clinical trials. Furthermore, the study results emphasize the importance of data sharing to define the genomic landscape and targeted treatment opportunities for the large group of rare pediatric cancers we encounter in clinical practice.

References

Harris P, Taylor R, Thielke R, Payne J, Gonzalez N, Conde J . Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2008; 42(2):377-81. PMC: 2700030. DOI: 10.1016/j.jbi.2008.08.010. View

Bhakta N, Liu Q, Ness K, Baassiri M, Eissa H, Yeo F . The cumulative burden of surviving childhood cancer: an initial report from the St Jude Lifetime Cohort Study (SJLIFE). Lancet. 2017; 390(10112):2569-2582. PMC: 5798235. DOI: 10.1016/S0140-6736(17)31610-0. View

Allen C, Laetsch T, Mody R, Irwin M, Lim M, Adamson P . Target and Agent Prioritization for the Children's Oncology Group-National Cancer Institute Pediatric MATCH Trial. J Natl Cancer Inst. 2017; 109(5). PMC: 5963793. DOI: 10.1093/jnci/djw274. View

Pearson A, Herold R, Rousseau R, Copland C, Bradley-Garelik B, Binner D . Implementation of mechanism of action biology-driven early drug development for children with cancer. Eur J Cancer. 2016; 62:124-31. DOI: 10.1016/j.ejca.2016.04.001. View

Schienda J, Church A, Corson L, Decker B, Clinton C, Manning D . Germline Sequencing Improves Tumor-Only Sequencing Interpretation in a Precision Genomic Study of Patients With Pediatric Solid Tumor. JCO Precis Oncol. 2021; 5. PMC: 8710335. DOI: 10.1200/PO.21.00281. View

Siegel D, Richardson L, Henley S, Wilson R, Dowling N, Weir H . Pediatric cancer mortality and survival in the United States, 2001-2016. Cancer. 2020; 126(19):4379-4389. PMC: 9539939. DOI: 10.1002/cncr.33080. View

Suh E, Stratton K, Leisenring W, Nathan P, Ford J, Freyer D . Late mortality and chronic health conditions in long-term survivors of early-adolescent and young adult cancers: a retrospective cohort analysis from the Childhood Cancer Survivor Study. Lancet Oncol. 2020; 21(3):421-435. PMC: 7392388. DOI: 10.1016/S1470-2045(19)30800-9. View

Garcia E, Minkovsky A, Jia Y, Ducar M, Shivdasani P, Gong X . Validation of OncoPanel: A Targeted Next-Generation Sequencing Assay for the Detection of Somatic Variants in Cancer. Arch Pathol Lab Med. 2017; 141(6):751-758. DOI: 10.5858/arpa.2016-0527-OA. View

van Tilburg C, Pfaff E, Pajtler K, Langenberg K, Fiesel P, Jones B . The Pediatric Precision Oncology INFORM Registry: Clinical Outcome and Benefit for Patients with Very High-Evidence Targets. Cancer Discov. 2021; 11(11):2764-2779. PMC: 9414287. DOI: 10.1158/2159-8290.CD-21-0094. View

10.

Chakravarty D, Gao J, Phillips S, Kundra R, Zhang H, Wang J . OncoKB: A Precision Oncology Knowledge Base. JCO Precis Oncol. 2017; 2017. PMC: 5586540. DOI: 10.1200/PO.17.00011. View

11.

Pugh T, Morozova O, Attiyeh E, Asgharzadeh S, Wei J, Auclair D . The genetic landscape of high-risk neuroblastoma. Nat Genet. 2013; 45(3):279-84. PMC: 3682833. DOI: 10.1038/ng.2529. View

12.

Newman S, Nakitandwe J, Kesserwan C, Azzato E, Wheeler D, Rusch M . Genomes for Kids: The Scope of Pathogenic Mutations in Pediatric Cancer Revealed by Comprehensive DNA and RNA Sequencing. Cancer Discov. 2021; 11(12):3008-3027. PMC: 8783930. DOI: 10.1158/2159-8290.CD-20-1631. View

13.

Karczewski K, Francioli L, Tiao G, Cummings B, Alfoldi J, Wang Q . The mutational constraint spectrum quantified from variation in 141,456 humans. Nature. 2020; 581(7809):434-443. PMC: 7334197. DOI: 10.1038/s41586-020-2308-7. View

14.

Abo R, Ducar M, Garcia E, Thorner A, Rojas-Rudilla V, Lin L . BreaKmer: detection of structural variation in targeted massively parallel sequencing data using kmers. Nucleic Acids Res. 2014; 43(3):e19. PMC: 4330340. DOI: 10.1093/nar/gku1211. View

15.

Trotman J, Armstrong R, Firth H, Trayers C, Watkins J, Allinson K . The NHS England 100,000 Genomes Project: feasibility and utility of centralised genome sequencing for children with cancer. Br J Cancer. 2022; 127(1):137-144. PMC: 9276782. DOI: 10.1038/s41416-022-01788-5. View

16.

Parsons D, Janeway K, Patton D, Winter C, Coffey B, Williams P . Actionable Tumor Alterations and Treatment Protocol Enrollment of Pediatric and Young Adult Patients With Refractory Cancers in the National Cancer Institute-Children's Oncology Group Pediatric MATCH Trial. J Clin Oncol. 2022; 40(20):2224-2234. PMC: 9273376. DOI: 10.1200/JCO.21.02838. View

17.

. RACE Act Poised to Advance Pediatric Cancer Research. Cancer Discov. 2020; 10(10):1434. DOI: 10.1158/2159-8290.CD-NB2020-081. View

18.

Murciano-Goroff Y, Drilon A, Stadler Z . The NCI-MATCH: A National, Collaborative Precision Oncology Trial for Diverse Tumor Histologies. Cancer Cell. 2021; 39(1):22-24. PMC: 10640715. DOI: 10.1016/j.ccell.2020.12.021. View

19.

Church A, Corson L, Kao P, Imamovic-Tuco A, Reidy D, Doan D . Molecular profiling identifies targeted therapy opportunities in pediatric solid cancer. Nat Med. 2022; 28(8):1581-1589. PMC: 10953704. DOI: 10.1038/s41591-022-01856-6. View

20.

Mangat P, Halabi S, Bruinooge S, Garrett-Mayer E, Alva A, Janeway K . Rationale and Design of the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. JCO Precis Oncol. 2019; 2018. PMC: 6312096. DOI: 10.1200/PO.18.00122. View